
Day One at CPHI Frankfurt Sees Announcements from ACG and Bora Pharmaceuticals
Key Takeaways
- ACG is expanding its European operations, enhancing supply chain resilience, and showcasing its capsule and sustainable packaging products at CPHI Frankfurt.
- Bora Pharmaceuticals is focusing on CDMO innovation, expanding fill/finish capabilities, and participating in strategic discussions at CPHI.
ACG showcased the expansion of its European presence, and Bora Pharmaceuticals participates in a discussion about CDMO innovation.
Which products is ACG exhibiting?
At stand 8.0T60 Zone Excipients, ACG is also exhibiting its gelatin capsule portfolio, which is now manufactured in Europe, and includes inhalation capsules, TiO2 -free options, liquid-fill formats, and a cellulose-based capsule with a pH-independent profile for moisture-sensitive formulations. The company’s range of high- and ultra-high barrier blister packaging is also on display.
“ACG is driving sustainability through PVC free and design for recyclability thermoforming options, PVC and halogen free cold forming material and lighter weight materials. ACG’s CelluPod, a paper-based blister and Bio D, a biodegradable PVC film. ACG’s packaging materials are produced from premium and traceable raw materials and are fully compliant with global regulations, provides reliability and consistence in product quality,” Jochen Scheil, ACG’s Vice President Global Sales & Business Development said in a press release (1).
“Our focus is on being in Europe, for Europe, combining global expertise with local presence to deliver real value for our customers,” said Selwyn Noronha, CEO of ACG Capsules, in the release (1). “By strengthening our operations in Croatia, we’re increasing capacity, shortening lead times and enhancing supply chain resilience. Together with our integrated solutions and deep understanding of European standards, this investment ensures we remain a trusted partner, always at our customers’ side.”
How will innovation in outsourcing be discussed this year?
The CEO of 
Look for our 
The company will also be announcing the expansion of its fill/finish capabilities in the CDMO Zone at Booth 6.0C90. In addition, the company’s Chairman and CEO, Bobby Sheng is a finalist for “CEO of the Year” in the 
“Bringing leaders and ideas together under one roof to collaborate is critical to the future growth of our industry,” said Mowery in a press release (2). “This has been an exciting year at Bora, marked by global growth and strategic investments across our business. We’re eager to make the most of the connections and collaboration at CPHI and carry those insights back to our customers to further strengthen the value we deliver.”
“Our collaboration with Bora Pharmaceuticals for sterile fill and finish services truly distinguishes us from other biologic CDMOs,” Marc Goemans, chief commercial officer of Bora Biologics, emphasized. “It streamlines the client experience by allowing them to sign a single agreement to work with one team on one timeline, ensuring expedited project success from start to finish—consolidating expertise and rewarding collaboration to de-risk every project."
The 
References
- ACG. ACG Showcases Strengthened European Capabilities and Croatia Expansion at CPHI 2025. Press Release. Oct. 28, 2025
- Bora Pharmaceuticals. Bora Pharmaceuticals Joins Global Pharma Leaders at CPHI 2025. Press Release. Oct. 27, 2025.
- Mirasol, F. CPHI Frankfurt Reveals 2025 Pharma Awards Finalists for Bio/Pharma Development. PharmTech.com. Sept. 18, 2025. https://www.pharmtech.com/view/cphi-frankfurt-reveals-2025-pharma-awards-finalists-for-bio-pharma-development 
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





